You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 麗珠集團午後直線拉漲逾5% 注射用艾普拉唑鈉被納入醫保目錄
格隆匯 11-28 13:23
格隆匯11月28日丨麗珠集團(000513.SZ)午後直線拉昇,現報32.58元,漲5.03%,暫成交2.3億元,最新總市值304億元。麗珠集團午間發公告稱,公司產品注射用艾普拉唑鈉被納入醫保目錄,該藥品適用於治療消化性潰瘍出血。據悉,約定的藥品醫保支付標準有效期為2020年1月1日至2021年12月31日。麗珠集團表示,本次納入醫保目錄的公司獨家品種注射用艾普拉唑鈉於2018年1月獲批生產,2018年度銷售額為1081.91萬元;2019年1-9月銷售額為5684.10萬元,約佔國內PPI注射劑銷售總額的0.48%。中金公司曾發研報指,麗珠集團品種結構逐漸優化,研發體系逐漸精細,考慮到估值切換和產品結構優化,維持其A股“跑贏行業”評級,升目標價至37元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account